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In cells infected by HIV-1 mutants lacking a functional Vif protein, APOBEC3G is specifically packaged into progeny virions and then
interferes with the process of virus infection. Here, we show that incorporation of APOBEC3G into HIV-1 virions is mediated by the specific
interaction of APOBEC3G with the carboxy-terminal nucleocapsid/p6 domain of the Gag polyprotein precursor. As a result, HIV-1 virus-like
particles that lack the nucleocapsid domain fail to package APOBEC3G. Surprisingly, RNA was also found to be essential for formation of
the nucleocapsid–APOBEC3G complex in vitro, thus raising the possibility that RNA may form a bridge between these two proteins.
D 2004 Elsevier Inc. All rights reserved.
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In cells infected with wild-type HIV-1, the host
antiretroviral defense protein APOBEC3G is bound by the
viral Vif protein and then targeted for degradation by the
proteasome (Conticello et al., 2003; Marin et al., 2003;
Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2003). In
contrast, in APOBEC3G-expressing cells infected by HIV-1
mutants lacking a functional Vif protein, APOBEC3G is
specifically packaged into progeny HIV-1 virions and then
interferes with the process of reverse transcription by
massively editing the nascent proviral DNA minus strand
(Harris et al., 2003; Mangeat et al., 2003; Zhang et al.,
2003). A key question is how APOBEC3G is selectively
incorporated into HIV-1 virions, a step that is critical for the
antiretroviral activity of APOBEC3G. However, as APO-
BEC3G can also inhibit the activity of a range of other
retroviruses, including the only very distantly related murine0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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one would predict that the virion binding sites for
APOBEC3G are likely to be highly conserved. Here, we
demonstrate that APOBEC3G incorporation into HIV-1
virions is mediated by the conserved nucleocapsid (NC)
domain of Gag acting in concert with RNA.Results
Although it is well established that virion packaging of
APOBEC3G represents a key step in the mechanism of
action of this host antiretroviral defense factor (Mariani et
al., 2003; Marin et al., 2003; Sheehy et al., 2003; Stopak et
al., 2003), it has been unclear how APOBEC3G is able to
specifically associate with progeny HIV-1 virions. To
address this question, we first asked whether APOBEC3G
would be able to inhibit the infectivity of pseudotyped HIV-
1 virions produced in the absence of six of the nine HIV-1
gene products, that is, in the absence of Env, Tat, Vpu, Vpr,
Vif, and Nef, as well as in the absence of the bulk of the
viral RNA genome. For this purpose, we used the pLL3.7
lentiviral vector (Fig. 1A), which retains only the minimal04) 163–168
Fig. 1. Inhibition of the infectivity of pseudotyped minimal HIV-1 virions by hAPOBEC3G. (A) Schematic structure of the LL3.7 lentiviral vector. CMV,
cytomegalovirus promoter; C, RNA packaging sequence; cPPT, central polypurine tract; EGFP, enhanced green fluorescent protein gene; WRE, woodchuck
hepatitis virus response element; SIN LTR, self-inactivating long terminal repeat retaining R and U5 but lacking almost all of U3. (B through G) Fluorescence
images of cells infected with LL3.7 virions produced in the presence or absence of hAPOBEC3G, mAPOBEC3, and/or HIV-1 Vif, as indicated.
Rapid Communication164cis-acting sequence elements required for HIV-1 genome
packaging (i.e., the C sequence) and reverse transcription
(i.e., the primer binding site, the polypurine tracts (PPT) and
part of the LTR) (Fig. 1A) (Rubinson et al., 2003). In
addition, this vector encodes enhanced green fluorescent
protein (EGFP) transcribed under the control of a cytome-
galovirus (CMV) promoter element (Fig. 1A). pLL3.7 was
packaged into virions by co-transfection into 293T cells
together with plasmids expressing the vesicular stomatitis
virus G (VSV-G) protein and the HIV-1 gag and pol genes
as well as a plasmid expressing HIV-1 Rev. The 293T cells
were also co-transfected with vectors expressing human
APOBEC3G (hAPOBEC3G), mouse APOBEC3 (mAPO-
BEC3) and/or HIV-1 Vif (Bogerd et al., 2004). Released
LL3.7 virions were then used to infect a second culture of
293T cells.
As shown in Fig. 1B, the LL3.7 lentiviral vector was able
to efficiently transduce 293T cells with the EGFP gene. Co-
expression of hAPOBEC3G or mAPOBEC3 resulted,
however, in an almost complete inhibition of EGFP trans-
duction (Fig. 1C and D). Additional co-expression of HIV-1
Vif fully restored the infectivity of LL3.7 virions produced
in the presence of hAPOBEC3G (Fig. 1F) but did not
relieve the inhibition caused by mAPOBEC3 (Fig. 1G), as
also previously demonstrated for wild-type HIV-1 virions
(Mariani et al., 2003). We therefore conclude that APO-
BEC3G is able to block the infectivity of HIV-1 virions
containing only the HIV-1 Gag and Pol proteins and very
limited segments from the viral RNA genome. These data
therefore confirm and extend a previous report showing that
hAPOBEC3G can inhibit the infectivity of HIV-1 virionsproduced in the presence of HIV-1 Gag, Pol, Rev, and Tat
but in the absence of Env, Vpu, Vif, Vpr, and Nef (Mangeat
et al., 2003).
As hAPOBEC3G is able to inhibit the infectivity of the
LL3.7 virions analyzed in Fig. 1, these should share the
ability of HIV-1 virions produced in the presence of all the
viral proteins except Vif to specifically package an HA
epitope tagged form of hAPOBEC3G. To confirm this
hypothesis, we transfected 293T cells with pLL3.7 together
with psynGag/Pol, a Rev-independent, codon optimized
Gag/Pol expression plasmid (Cowan et al., 2002), and a
plasmid-expressing hAPOBEC3G-HA (Bogerd et al.,
2004). As shown in lane 1 of Fig. 2B, virions released
from this culture were indeed able to package hAPO-
BEC3G-HA effectively. This packaging was specific, as no
hAPOBEC3G-HA was recovered from the supernatant
media of 293T cells transfected with hAPOBEC3G-HA
and pLL3.7 in the absence of the psynGag/Pol expression
plasmid (Fig. 2B, lane 5). Moreover, a control HA-tagged
cytoplasmic protein of similar size, h-arrestin 2 (Oakley et
al., 2000), was not detectably packaged into released HIV-1
virions (Fig. 2B, lane 6).
To more accurately determine the requirements for
hAPOBEC3G-HA packaging into HIV-1 virions, we also
generated non-infectious virions produced in the absence of
a packageable RNA genome (Fig. 2, lane 2), in the presence
of only the Gag polyprotein and the protease component of
pol (Fig. 2, lane 3) and finally in the presence of only the
Gag polyprotein (Fig. 2, lane 4). In all cases, hAPOBEC3G-
HA continued to be efficiently packaged into the released
HIV-1 virion particles (Fig. 2B, lanes 2 to 4). We therefore
Fig. 2. The HIV-1 Gag polyprotein is sufficient for virion packaging of hAPOBEC3G. (A) Western analysis of the lysates of virion producer cells using HIV-1
capsid (upper panel) or HA epitope tag-specific mouse monoclonal antibodies (lower panel). (B) HIV-1 virions released by the cultures analyzed in panel A
were collected and also subjected to Western blot. For both panels, 293T cells were transfected with: lane 1, 1 Ag of pLL3.7, 500 ng of psynGag/Pol and 500 ng
of ph3G-HA; lane 2, 500 ng of psynGag/Pol and 500 ng ph3G-HA; lane 3, 500 ng of psynGag/Pro and 500 ng ph3G-HA; lane 4, 500 ng of psynGag and 500
ng ph3G-HA; lane 5, 1 Ag of pLL3.7 and 500 ng of ph3G-HA; lane 6, 1 Ag of pLL3.7, 500 ng of psynGag/Pol and 500 ng of phARR-2-HA. Levels of
transfected DNA were held constant by supplementation to 2 Ag per transfection with a control plasmid. (C) Similar to panel A. (D) Similar to panel B. For
panels C and D, 293T cells were transfected with: lane 1, 1 Ag of pLL3.7 and 500 ng of ph3G-HA; lane 2, 500 ng of psynGag and 500 ng of ph3G-HA; lane 3,
500 ng of psynGag/ZWT and 500 ng of ph3G-HA.
Rapid Communication 165conclude that the HIV-1 Gag polyprotein precursor is the
only viral protein required for virion incorporation of
hAPOBEC3G.
If HIV-1 Gag mediates hAPOBEC3G packaging, then
Gag should contain one or more specific binding sites for
hAPOBEC3G. To test this hypothesis, we used in vitro
translation in the presence of 35S-methionine to synthesize
the full-length ~55 kDa Gag precursor, or portions of Gag
consisting of the ~17 kDa matrix (MA) protein, the ~24
kDa capsid (CA) protein or the ~16 kDa carboxy terminal
region of Gag, consisting of the ~7 kDa NC protein linked
to p6 (Fig. 3A). Recombinant hAPOBEC3G-HA was
prepared by overexpression in transfected 293T cells and
was recovered from the lysate by incubation in the presence
of an HA affinity matrix (Fig. 3C). Mock-transfected 293T
cells served as a negative control. After loading with
hAPOBEC3G-HA, the HA affinity matrix was incubated
with the 35S-labeled Gag proteins and bound proteins
recovered by centrifugation. As shown in Fig. 3B, we noted
specific binding of the full-length Gag protein to the
hAPOBEC3G-HA loaded affinity matrix but not to the
control matrix (lanes 1 and 2). In addition, we also
observed strong binding of the NC/p6 protein to the
hAPOBEC3G-HA matrix (lanes 7 and 8) but no detectable
binding of either the HIV-1 MA or CA protein (lanes 3 to6). We therefore conclude that hAPOBEC3G specifically
interacts with the NC/p6 domain of the Gag polyprotein
precursor and that this interaction likely mediates pack-
aging of hAPOBEC3G into HIV-1 virion particles. We note
that as this experiment used proteins recovered from
expressing cells (APOBEC3G-HA) or translated in a
reticulocyte lysate (NC/p6), we cannot be certain that the
observed interaction is direct.
It has previously been demonstrated that hAPOBEC3G
can inhibit the infectivity of a wide range of retroviruses,
including HIV-1 as well as other primate and non-primate
lentiviruses and the distinct oncoretrovirus murine leukemia
virus (MLV) (Mangeat et al., 2003; Mariani et al., 2003). It
therefore seems probable that packaging of hAPOBEC3G
must involve one of the few protein sequence motifs that are
conserved across the lentivirus and oncoretrovirus families.
APOBEC3G specifically binds to the carboxy-terminal ~16
kDa of the ~55 kDa HIV-1 Gag polyprotein, which includes
the ~7 kDa NC protein as well as p6 (Fig. 3). However, p6 is
not conserved in MLV, thus suggesting that NC may be key
for hAPOBEC3G incorporation into HIV-1 virions.
To directly test whether the HIV-1 NC protein mediates
hAPOBEC3G incorporation into progeny virions, we took
advantage of the previous observation (Accola et al., 2000)
that the NC domain of HIV-1 Gag, which is normally
Fig. 3. The hAPOBEC3 protein specifically interacts with the NC/p6
domain of the Gag polyprotein. (A) 35S-methionine-labeled forms of the
full-length approximately 55 kDa Gag polyprotein (lanes 1 and 2), the
approximately 24 kDa CA protein (lanes 3 and 4), the approximately 17
kDa MA protein (lanes 5 and 6) and the approximately 16 kDa carboxy-
terminal domain of Gag, consisting of NC and p6 as well as the p2 and p1
spacers, were generated by in vitro translation. This gel shows the input-
labeled proteins used in the binding reaction, as well as molecular weight
markers. (B) This panel shows the 35S-labeled proteins retained by an HA
affinity matrix loaded with HA-APOBEC3G expressed in 293T cells (+).
The negative control lanes () used a 293T cell lysate lacking HA-
APOBEC3G. (C) Expression of HA-APOBEC3G in 293T cells transfected
with ph3G-HA or with the control pcDNA3 plasmid was visualized by
Western analysis. These lysates were used to load the HA affinity matrix
utilized in panel B.
Rapid Communication166essential for virion production, can be functionally sub-
stituted with a 34 aa leucine zipper derived from the yeast
GCN4 protein. Although this substitution effectively res-
cues virion production, it does not rescue viral infectivity.
We precisely substituted this GCN4 coding sequence,
termed ZWT (Accola et al., 2000), in place of sequences
encoding the 7 kDa NC protein, and a flanking 1 kDa spacer
peptide, leaving behind fully intact forms of the HIV-1 Gag
matrix, capsid, and p6 domains. As shown in Fig. 2C and D,
the Gag-ZWT protein is effectively expressed and gives rise
to levels of virus-like particles that are similar to those seen
with HIV-1 Gag. However, these NC-deficient virions differ
from the wild-type HIV-1 Gag particles in that they do not
incorporate detectable levels of hAPOBEC3G (Fig. 2D, lane3). Therefore, the NC protein indeed plays an essential role
in mediating virion packaging of APOBEC3G, as predicted
by the in vitro binding data presented in Fig. 3.
A key function of the NC domain of Gag in the retroviral
life cycle is the specific incorporation of the viral RNA
genome into virion particles. While the NC domain of Gag
is therefore critical for the specific interaction of the Gag
precursor with the viral RNA genome, NC can also interact
with RNA non-specifically (Dorfman et al., 1993; Gorelick
et al., 1993). We have presented evidence demonstrating
that the viral RNA genome is not required for hAPOBEC3G
packaging into HIV-1 virion particles (Fig. 2) or for
hAPOBEC3G binding by the NC/p6 protein (Fig. 3).
However, it remains possible that non-specific RNA binding
by NC is important.
To test this hypothesis, we subjected both the HA-affinity
matrix-bound hAPOBEC3G protein and the in vitro
translated NC/p6 protein to exhaustive digestion with
RNase A. Interestingly, this digestion resulted in the loss
of a slower migrating form of the NC/p6 fusion protein (see
asterisk in Fig. 4A) and an increase in the intensity of the
protein band migrating at the predicted approximately 16
kDa size (compare lanes 4 to 6 with lanes 1 to 3 in Fig. 4A).
We therefore hypothesize that this slower migrating band
represents a NC–RNA complex that remains stable even
when subjected to electrophoresis through an SDS–poly-
acrylamide gel. We note that less complete digestion with
RNase A, as performed in Fig. 3, did not result in loss of
this hypothetical complex (see lanes 7 and 8 in Fig. 3A) and
indeed did not completely remove all RNA (data not
shown).
The key observation shown in Fig. 4B is, however, the
finding that exhaustive RNase A digestion effectively
blocks hAPOBEC3G binding by the NC/p6 protein. We
therefore conclude that RNA plays an essential role in
supporting the interaction of NC with hAPOBEC3G. While
the RNA may simply be important for maintaining NC in a
functional conformation, we note that hAPOBEC3G can
bind RNA directly (Yu et al., 2004), thus raising the
possibility that RNA plays a direct role in mediating
formation of a hAPOBEC3G–NC complex, perhaps by
acting as a bridge.Discussion
In this manuscript, we have sought to identify the basis
for the selective incorporation of hAPOBEC3G into virion
particles. We have demonstrated that Gag is the only viral
protein required for hAPOBEC3G incorporation (Fig. 2),
that hAPOBEC3G specifically interacts with the NC/p6
domain of HIV-1 Gag (Fig. 3), that NC is essential for
incorporation of hAPOBEC3G into HIV-1 virus-like par-
ticles (Fig. 2), and perhaps most surprisingly, that non-
specific RNA plays a critical role in mediating hAPO-
BEC3G binding by the HIV-1 NC protein in vitro (Fig. 4).
Fig. 4. hAPOBEC3G binding to HIV-1 NC/p6 is mediated by RNA. This
binding assay was performed as described in Fig. 3, except that the
hAPOBEC3G-HA and NC/p6 proteins were either not treated with RNase
A or were subjected to exhaustive treatment with RNase A before binding.
(A) These gels show the 35S-labeled input NC/p6 proteins used in the
binding reaction. Note that exhaustive RNase A digestion results in the loss
of a slower migrating form of the approximately 16 kDa NC/p6 protein
(asterisk) that we hypothesize is a complex of NC/p6 with RNA. (B) In
vitro binding of the 35S-labeled NC/p6 protein to HA-APOBEC3G. Mock-
transfected 293T cells, or cells transfected with a plasmid expressing HA-
tagged h-arrestin 2 (harr2) provided negative control cell lysates. (C)
Western analysis of the 293T cell lysates used to load the HA affinity matrix
used in panel B, using a mouse anti-HA monoclonal antibody.
Rapid Communication 167Given that hAPOBEC3G is able to inhibit the replication of
a wide range of retroviruses (Mangeat et al., 2003; Mariani
et al., 2003), it will be of interest to determine which
conserved attributes of retroviral NC proteins are critical for
specific binding to hAPOBEC3G.
While this manuscript was in preparation, two other
groups also reported experiments designed to analyze the
requirements for APOBEC3G into HIV-1 virions. While
Cen et al. (2004) also found that the NC domain of Gag was
critical for APOBEC3G incorporation, they differed in that
they did not observe any requirement for RNA. In contrast,
Svarovskaia et al. (2004) reported that APOBEC3G
incorporation into virions required RNA, but did not depend
on the NC domain. Our results may reconcile these very
different conclusions by demonstrating that, while NC is
indeed critical for APOBEC3G incorporation into virions
(Fig. 2) and specific binding of APOBEC3G by Gag (Fig.
3), this interaction is also dependent on the presence of non-specific RNA which in our hands was only removed by
exhaustive digestion with RNase A (Fig. 4).Materials and methods
Immunofluorescence analysis
293T cells were transfected with 1 Ag of the pLL3.7
lentiviral vector plasmid together with 250 ng of each of
the packaging plasmids pVSV-G, pRSV-Rev and pMDL-
gag/pol RRE (Rubinson et al., 2003). The cells were also
co-transfected with 500 ng of ph3G-HA or pm3-HA, or
500 ng of pcDNA3.1 as a negative control. Finally, the
cells were also co-transfected with 250 ng of pgVif or the
pgDVif control plasmid (Bogerd et al., 2004). At 48 h after
transfection, the virus containing supernatant media were
harvested, passed through a 0.45-Am filter and used to
infect 293T cells grown on coverslips. At 36 h post-
infection, EGFP expression was visualized by fluorescence
microscopy.
Western analyses
293T cells were transfected with a combination of HIV-1
RNA and/or Gag expression plasmids, together with a
plasmid expressing an HA-tagged form of APOBEC3G, as
described in the legend of Fig. 2. At 44 h after transfection,
the producer cells and the supernatant media were harvested
for Western analysis. Released virions were collected by
pelleting through a sucrose cushion (Bogerd et al., 2004),
resuspended and then normalized for minor differences in
p24 production as determined by ELISA. Both the cell and
virion lysates were prepared and analyzed by Western blot
as previously described (Bogerd et al., 2004) using mouse
monoclonal antibodies specific for HIV-1 capsid (Chesebro
et al., 1992) or the HA epitope tag (Covance). All the
plasmids used in these experiments have been previously
described (Cowan et al., 2002; Rubinson et al., 2003;
Bogerd et al., 2004) except for psynGag-ZWT, which is
identical to psynGag except that the NC domain and the
adjacent p1 spacer have been precisely substituted with a
leucine zipper derived from residues 247 to 280 of the yeast
GCN4 protein, as previously described (Accola et al.,
2000).
In vitro binding assays
35S-methionine-labeled Gag proteins were generated by
in vitro translation using a TNT coupled transcription/
translation system. In parallel, 293T cells were transfected
with 1.5 Ag of ph3G-HA (Bogerd et al., 2004) or the
pcDNA3.1 control plasmid. Forty-eight hours after trans-
fection, cultures were suspended in lysis buffer (50 mM
TRIS, pH 7.4; 150 mM NaCl; 0.5% NP40), cleared by
centrifugation, and then added to 250 Al of HA affinity
Rapid Communication168matrix (Covance). After binding for 1 h at 4 8C, equal
aliquots of the bound fraction were either taken for Western
blot analysis, using a monoclonal mouse antibody specific
for the HA epitope tag, or added to 20 Al of each in vitro
translated Gag protein. All samples were then treated with
150 Ag of RNase A (Quiagen) for 10 min at 37 8C. After
additional binding for 1 h at 4 8C, the HA affinity matrix
samples were extensively washed with lysis buffer and
bound proteins eluted and detected by SDS-PAGE and
radiofluorography.
In the experiment shown in Fig. 4, hAPOBEC3G-HA
and h-arrestin 2-HA were recovered from expressing 293T
cells, as described above, and the loaded HA affinity matrix
washed twice with lysis buffer. The bound HA-tagged
proteins were then incubated at 37 8C for 15 min, in the
presence or absence of 150 Ag of RNase A, before being
washed once more in lysis buffer. Simultaneously, the 35S-
labeled NC/p6 protein was incubated at 37 8C for 15 min in
the presence or absence of 150 Ag of RNase A. Binding and
analysis were performed as described above.Acknowledgments
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